What's new

[Cyprus Times] Vaccine had 73% effectiveness in infants, Pfizer claims

pfizer.jpg
[/ATTACH]
The vaccine was 73% effective in infants, Pfizer claims The company has announced that it is developing a version of the vaccine for children, specifically for Omicron subvariants

Pfizer-BioNTech's Covid-19 vaccine was 73% effective in protecting infants - ages 6 months to 4 years - during the period when the Omicron variant of the coronavirus was highly prevalent, pharmaceutical company Pfizer announced Tuesday.

The U.S. Food and Drug Administration (FDA) gave approval on June 17 to administer the vaccine in this age group.

The infants in the study received either three doses (3 μg) of the Pfizer-BioNTech vaccine or placebo. The vaccine's efficacy was 73.2% in infants aged 6 months to 4 years, according to results released by the two pharmaceutical companies.

"While these results confirm that the three 3 μg doses of our 3 μg Covid-19 vaccine provided infants with a high level of protection at a time when the Omicron BA.2 sub variant was highly prevalent, (...) we are also developing a bivalent anti-Omicron BA.4/BA.5 vaccine tailored to this age group to address these sub-variant variants," said Ugur Shahin, CEO and co-founder of BioNTech.

Source: Cyprus Times


Contents of this article including associated images are belongs to Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times

Source
 
Back
Top